The Quantellect read.As of Nov 19, 2026, 23 active firms cover Biogen Inc: 15 rate it Buy or better, 7 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets span $175.00 to $310.00, a moderate spread. The average target of $247.29 sits 2% below the current $251.47. The rating mix has stayed broadly stable, with Buy-side ratings easing from 16 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.57 next quarter toward $16.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS23 active firms
Buy
Strong Buy00%
Buy1565%
Neutral730%
Sell14%
Strong Sell00%
Based on 23 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$247.29
-1.7% downside
Average target across 21 active firms as of Nov 19, 2026 vs $251.47 current
Highest Target$310.00
Average Target$247.29
Lowest Target$175.00
Detailed analyst forecasts for BIIB
Showing 1–24 of 24 named analysts shown · 23 active firms in the rating projection
As of Nov 19, 2026, 15 of 23 active firms rate BIIB a Buy (7 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BIIB EPS & revenue forecast
EPS · NEXT QUARTER
$3.57
Range $2.93 – $4.18 · 13 analysts · +0% YoY
Next period, 13 analysts expect Biogen Inc to earn $3.57 a share (range $2.93 – $4.18), versus $3.57 a year earlier. Full-year consensus is $12.54, growing to $16.25 the year after.
REVENUE · NEXT QUARTER
$2.6B
Range $2.4B – $2.7B · 13 analysts · +5% YoY
Revenue is expected to reach $2.6B (range $2.4B – $2.7B), +5.3% year-over-year. Full-year consensus is $10.6B, rising to $10.8B next year.
Top analysts covering Biogen Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIIB.
#1
Laura Chico
Wedbush · Rank #55
Neutral
$212.00-15.7% to target
Overall win rate
46%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$251.00-0.2% to target
Overall win rate
45%
+ Follow
#3
Yatin Suneja
Guggenheim · Rank #84
Buy
$280.00+11.3% to target
Overall win rate
50%
+ Follow
#4
Ami Fadia
Needham · Rank #92
Buy
$256.00+1.8% to target
Overall win rate
46%
+ Follow
#5
David Amsellem
Piper Sandler · Rank #124
Buy
$245.00-2.6% to target
Overall win rate
50%
+ Follow
BIIB stock forecast FAQ
What is BIIB's average 12-month price target?+
The 21 active firms with a live target average $247.29 for Biogen Inc over the next 12 months, ranging from a $310.00 high to a $175.00 low, as of Nov 19, 2026.
Is BIIB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 23 active firms as of Nov 19, 2026, 15 rate it Buy or Strong Buy, 7 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BIIB?+
The Street-high target is $310.00 (Wells Fargo), and the Street-low is $175.00 (HSBC). The average of all 21 active-firm targets is $247.29.
How many active Wall Street firms cover BIIB?+
23 active firms have a recognized rating on Biogen Inc as of Nov 19, 2026, and 21 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BIIB?+
Among analysts who currently cover BIIB, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Neutral with a $212.00 target.
What is Biogen Inc's projected EPS for next quarter?+
The consensus estimate is $3.57 per share (range $2.93 – $4.18) across 13 analysts. Full-year EPS is projected at $12.54, rising to $16.25 the following year.
How much revenue is Biogen Inc expected to report next quarter?+
Consensus revenue is $2.6B (range $2.4B – $2.7B). Full-year revenue is projected at $10.6B, growing to $10.8B next year.
Have analysts been upgrading or downgrading BIIB lately?+
As of Nov 19, 2026, 15 of 23 active firms rate BIIB a Buy (7 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIIB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.